modelTeriflunomide

Diagram of Teriflunomide

Extends from Pharmacolibrary.Drugs.ATC.L.L04AK02.

Information

name:Teriflunomide
ATC code:L04AK02
route:oral
compartments:2
dosage:14mg
volume of distribution:11.3L
clearance:0.23L/h
other parameters in model implementation

Teriflunomide is an oral immunomodulatory drug approved for the treatment of relapsing forms of multiple sclerosis (MS). It works by inhibiting the enzyme dihydroorotate dehydrogenase, thus interfering with de novo pyrimidine synthesis in rapidly dividing cells such as activated lymphocytes.

Pharmacokinetics

Population pharmacokinetics in adult patients with multiple sclerosis, both sexes, typical dose, without significant comorbidities.

References

  1. Kruger, TM, et al., & Ruixo, JJP (2023). Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. Clinical pharmacokinetics 62(11) 1533–1550. DOI:10.1007/s40262-023-01308-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37776485

  2. Shin, Y, et al., & Park, K (2023). Development of a population pharmacokinetic model and optimal dosing regimen of leflunomide in Korean population. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 184 106402–None. DOI:10.1016/j.ejps.2023.106402 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36754259

  3. Agarwal, S, et al., & Pal, TK (2012). Comparative bioequivalence study of leflunomide tablets in Indian healthy volunteers. Arzneimittel-Forschung 62(3) 145–148. DOI:10.1055/s-0031-1298024 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22278631

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)